Skip to main content

Day: October 27, 2021

Invitation to BTS Q3 2021 presentation and conference call

P R E S S R E L E A S E Stockholm, October 27, 2021 STOCKHOLM, SWEDEN – BTS Group AB (publ), a leading global strategy implementation firm, invites investors, analysts and business media to its interim report presentation and conference call with President and CEO Henrik Ekelund. Digital participation:Wednesday, November 10 at 09.30 am CET. The presentation can be followed on the web with opportunities to ask questions, or you may dial any of the following numbers: UK +44 333 300 9262 US +1 631 913 1422 SE +46-8 505 583 68 Follow the presentation at: https://tv.streamfabriken.com/bts-group-q3-2021 Registration is not required for participating at the webcast or the conference call. Physical participation: Erik Penser Bank, Apelbergsgatan 27, Stockholm Weblink for notification of physical participation at the presentation https://financialhearings.com/event/13472 The...

Continue reading

Acarix granted US CPT reimbursement code for CADScor System

Press release (MAR)Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category III CPT® (CPT III) code application for the Acarix CADScor System®. The application was actively endorsed by the American College of Cardiology (ACC) and accepted by AMA without remarks. CPT III reimbursement codes are assigned to emerging technologies, services, and procedures. In line with the CPT III process, the new code for the CADScor® system will be published by Center for Medicare and Medicaid services (CMS) on January 1st, 2022, and accessible to US payers and providers by July 1st, 2022. Per the process, there is no specific payment amount attached to the code and Acarix will now be working with selected payors to grant the level...

Continue reading

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Press release, Helsinki, 27 October 2021 at 9 AM (EEST) Nexstim Receives an NBS System Order from a Hospital in the Middle East Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces having received an NBS system order from a hospital in the Middle East. Nexstim’s NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. This specific NBS system also includes the software of an NBT® system, allowing the system to also be used for therapeutic treatments. Mikko Karvinen, CEO of Nexstim commented: “Even though our presence is the strongest in the North American and European markets, operating in markets such as the Middle East is important for us. We are happy to see internationally occurring interest in our systems that...

Continue reading

Heineken N.V. reports on 2021 third-quarter trading

Amsterdam, 27 October 2021 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) today publishes its trading update for the third quarter of 2021. KEY HIGHLIGHTSBeer volume -5.1% organically for the quarter; +4.0% for the first nine months Heineken® volume +8.0% in the quarter; +15.1% for the first nine months Full year expectations unchangedDolf van den Brink, Chairman of the Executive Board / CEO, commented: “As anticipated, our Asia Pacific region was deeply impacted by the pandemic in the third-quarter. We see first signs of recovery and I admire the resilience and solidarity of our people as we navigate these challenges. Our new EverGreen strategy is gathering momentum across the organisation. We continue to revitalise our portfolio with emphasis on premium, low- and no-alcohol and beyond beer. The Heineken® brand sustained...

Continue reading

Aspo Group subsidiary Telko Ltd has agreed to acquire shares of Estonian company Mentum AS

Aspo Plc Stock exchange release October 27, 2021, at 9 a.m. Aspo Group subsidiary Telko Ltd has agreed to acquire shares of Estonian company Mentum AS Aspo group subsidiary Telko Ltd has signed an agreement on the 26thof October 2021, by which Telko Ltd will acquire shares of Estonian company Mentum AS. Mentum is a strategic distribution partner in Baltic countries. It operates in the premium lubricants business in automotive, industrial and marine business. Mentum will complement perfectly Telko’s lubricant business in the Baltic Sea region. After the acquisition, Telko’s and Castrol’s cooperation, which has started in 1958, will cover Finland, Scandinavia and the Baltic countries. The acquisition will increase Telko’s sales by 10 million euros. The transaction will not significantly affect Telko’s profitability in 2022. The acquisition...

Continue reading

OP Corporate Bank plc’s Interim Report for 1 January–30 September 2021

OP Corporate Bank plc Interim Report 1 January–30 September 2021Stock Exchange Release 27 October 2021 at 9.00am EEST OP Corporate Bank plc’s Interim Report 1 for January–30 September 2021Consolidated earnings before tax improved to EUR 469 million (319). Total income increased by 24% to EUR 1,037 million (838). Investment income of EUR 214 million rose by EUR 76 million year on year. Net insurance income increased by 14% to EUR 528 million (463). Net interest income decreased by 4% to EUR 235 million (244). Total expenses increased by 10% to EUR 519 million (473). Impairment loss on receivables totalled EUR 25 million (65). Corporate Banking earnings before tax improved to EUR 279 million (194). Total income increased by EUR 63 million to EUR 498 million (434). Net investment income increased to EUR 128 million (104) million and net...

Continue reading

Karolinska Development’s portfolio company Dilafor recruits first patient to Phase 2a study of tafoxiparin in women diagnosed with preeclampsia

STOCKHOLM, SWEDEN – October 27, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Dilafor, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first patient in a clinical Phase 2a study with tafoxiparin in pregnant women diagnosed with preeclampsia. Dilafor has now enrolled the first patient in a Phase 2a pilot study that will investigate whether treatment with subcutaneously administered tafoxiparin can improve the outcome of preeclampsia. To explore the treatment efficacy and clinical benefit, ultrasound examinations of the mother and fetus as well as measurment of a panel of established biomarkers for preeclampsia will be performed. The exploratory, open label, randomized, parallel-group, Phase 2a pilot study will evaluate...

Continue reading

Construction contract (Porto Franco commercial building)

AS Nordecon group company Nordecon Betoon OÜ (brand name NOBE) and Mapri Ehitus OÜ as joint bidders entered into contract with Porto Franco OÜ for the construction of the building III of Porto Franco real estate development in Kai street Tallinn, during which a commercial building with three underground and five above-ground floors will be built. The cost of the works is 7.65 million euros plus value added tax. Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Sweden, Finland and Ukraine. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2020 was 296 million euros. Currently...

Continue reading

Ultimovacs ASA – Transactions by primary insiders and closely associated parties

Reference is made to the stock exchange announcement by Ultimovacs ASA (OSE: ULTI) (“Ultimovacs” or the “Company”) on 26 October 2021 regarding the successful placing of a private placement of new shares (the “Offer Shares”) with gross proceeds of NOK 270 million (the “Private Placement”). The following primary insiders or closely associated parties of such were allocated Offer Shares in the Private Placement. Gjelsten Holding AS, a closely associated party of Henrik Schüssler, board member of the Company, has subscribed for and been allocated 324,000 Offer Shares.Canica AS, a closely associated party of Aitana Peire, board member of the Company, has subscribed for and been allocated 170,794 Offer Shares.Sundt AS, a closely associated party of Leiv Askvig, board member of the Company, has subscribed...

Continue reading

DOVRE GROUP TRADING STATEMENT JANUARY 1 – SEPTEMBER 30, 2021 Dovre’s net sales and operating profit increased in Q3. Positive profit warning – raises guidance for 2021  

Dovre Group Plc                Stock exchange release                October 27, 2021 at 8.45 a.m. DOVRE GROUP TRADING STATEMENT JANUARY 1 – SEPTEMBER 30, 2021Dovre’s net sales and operating profit increased in Q3. Positive profit warning – raises guidance for 2021 Dovre Group Plc issues today a trading statement for the nine months ended on September 30, 2021. The figures presented in this trading statement are not audited. Last year’s corresponding period in parentheses. July – September 2021Net sales EUR 46.5 (16.5) million – increase 181.7%Project Personnel: net sales EUR 19.4 (13.4) million – increase 44.0% Consulting: net sales EUR 3.3 (3.1) million – increase 7.3% Renewable Energy: net sales EUR 23.9 (-) millionOperating profit EUR 2.7 (0.6) million – increase 340.3%Profit for the period EUR 1.5 (0.4) million...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.